Chime Biologics Appoints Vice President of Manufacturing

Talent is the core driving force behind Chime Biologics’ steady growth. Chime Biologics has a strong management team with extensive international knowledge and experience in biopharmaceutical industry, including R&D, process development, tech-transfer and scale-up, quality control, commercialization and international registration of biologics.

Vice President of Manufacturing with deep U.S. Manufacturing Management Experience

Thomas Matthew Risko

Vice President of Manufacturing

Thomas has over 35 years of manufacturing experience, including 25 years in biotechnology industry, in the production of therapeutic proteins, antibodies, and vaccines in the United States.  He is a manufacturing leader with experience in the production of several commercial blockbuster biologics and numerous clinical therapeutics. Previously Thomas held leadership, technical and commercial positions in Amgen Rhode Island, Regeneron Pharmaceuticals and Bio-Rad Laboratories.

Thomas received his bachelor’s degree in Biological Sciences from the State University of New York at Albany.

About CHIME BIOLOGICS

Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health.  For more information, please visit www.chimebiologics.com.